Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are at least 18 years old and able to give informed consent
- People who have a foot wound or ulcer classified as Wagner Grade 1 (a shallow wound that may be full or partial thickness); if the wound is near the ankle bone, no more than half of it can be above the midpoint of that bone (confirm with trial site)
- People whose wound, after cleaning, measures between 1 cm² and 20 cm² in size
- People whose wound has been present for at least 4 weeks before the screening visit
- People who have documented evidence of adequate blood flow to the affected area, based on one of several accepted tests (confirm with trial site for which tests apply)
- People whose other wounds, if any, are located at least 2 cm away from the main wound being studied
- People who have had any previous wound infections that have been fully treated according to established medical guidelines
- People who are able to use offloading or compression devices as required, have a stable home environment, and can attend follow-up appointments
- People who agree to have digital photos taken of their wound
- People joining the Miro3D treatment group must have a wound with a clean base, free of dead tissue or debris, at the time of treatment
Who may not be able to join:
- People whose wound has already shrunk by 30% or more after two weeks of standard care between the screening and baseline visits
- People with poorly controlled diabetes, indicated by an HbA1c level of 12% or higher
- People with active, untreated, or uncontrolled bone infection (osteomyelitis)
- People with cancer or blood vessel inflammation present at the wound site
- People currently receiving chemotherapy
- People currently on dialysis
- People who have used experimental drugs or treatments within the 30 days before screening
- People with health conditions that would make it difficult to safely participate in or complete the study (confirm with trial site)
- People with a known allergy or sensitivity to pig-derived materials
- People with third-degree burns
- People showing signs of worsening poor blood flow or gangrene at the time of screening
- People who have previously had radiation treatment at the wound site
- People whose wound exposes internal surgical hardware, implants, or fixation devices
- People who are transitioning to palliative or comfort-focused care
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert J. Snyder, DPM, Barry University
Phone: 954-721-4806
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percent Area Reduction (PAR) and Granulation Tissue Formation at 4 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.